Delving into the Latest Updates on Xiyuan Anjian Medicine (Shanghai) Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Congenital Disorders

Small molecule drug

Monoclonal antibody

Small molecule-drug conjugates

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	6
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2
Monoclonal antibody	2
Unknown	2
Small molecule-drug conjugates	1

Top 5 Target	Count

TGF-β(Transforming growth factor beta)	1
TrkA(Nerve growth factor receptor Trk-A)	1
NGF(Nerve growth factor)	1
CGRP(Calcitonin gene-related peptide)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

3

Preclinical

Phase 1 Clinical

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BR005-036C ( CGRP )	Migraine Disorders More	Phase 2
Recombinant humanized anti-TrkA monoclonal antibody(Brise Pharmaceutical) ( TrkA )	Low Back Pain More	Phase 1
BR007 ( TGF-β )	Camurati-Engelmann Syndrome More	Preclinical
BR009	Migraine Disorders More	Preclinical
BR008	Neuralgia More	Preclinical